NCT06458153 Imaging Speech in Neurotypical Adults and Individuals With Cerebellar Stroke
| NCT ID | NCT06458153 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of Pittsburgh |
| Condition | Stroke |
| Study Type | INTERVENTIONAL |
| Enrollment | 100 participants |
| Start Date | 2025-05-27 |
| Primary Completion | 2028-07 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 100 participants in total. It began in 2025-05-27 with a primary completion date of 2028-07.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this research study is to learn how the brain areas that plan and control movement interact with the areas responsible for hearing and perceiving speech in healthy adults and people who have had cerebellar strokes. The main questions it aims to answer are: 1. What regions of the brain's sensory systems show changes in their activity related to speech? 2. To what extent do these regions help listeners detect and correct speech errors? 3. What is the role of the cerebellum (a part of the brain in the back of the head) in these activities? Participants will be asked to complete several experimental sessions involving behavioral speech and related tests and non-invasive brain imaging using electroencephalography (EEG) and functional magnetic resonance imaging (fMRI).
Eligibility Criteria
Inclusion Criteria: Cohort 1 (neurotypical adults): * Age 18-49 * Right-handed * Native English speaker Cohort 2 (people with cerebellar lesions): * Age 18 or older * Right-handed * Native English speaker * History of cerebellar stroke Cohort 3 (controls matched to Cohort 2) * Age 18 or older * Right-handed * Native English speaker Exclusion Criteria: Cohort 1 (neurotypical adults): * Presence of MRI risk factors: metal and/or electromagnetic devices (e.g., pacemakers, neurostimulators) in the body, previous shrapnel injuries, use of an intrauterine device containing metal, claustrophobia, pregnant or possibly pregnant * History of neurological / neurodegenerative disease or severe brain injury (e.g., stroke or severe traumatic brain injury) * Hearing loss, defined by pure tone thresholds \>25 decibels (dB) hearing level (HL) at octave frequencies between 250-8000 Hz * Clinical diagnosis and/or treatment for schizophrenia or other psychotic disorders * Clinical diagnosis and/or treatment for neurocognitive disorders (e.g., dementia, delirium) * Presence of a severe and unmanaged, clinically diagnosed attention disorder * Clinically diagnosed with or treated for a speech, language, or hearing disorder * Head circumference greater than 60cm or weight greater than 300 pounds * History of severe claustrophobia * Currently pregnant Cohort 2 (people with cerebellar lesions): * Presence of MRI risk factors: metal and/or electromagnetic devices (e.g., pacemakers, neurostimulators) in the body, previous shrapnel injuries, use of an intrauterine device containing metal, claustrophobia, pregnant or possibly pregnant * History of neurological / neurodegenerative disease or severe brain injury other than stroke * Hearing loss, defined by pure tone thresholds \>50 dB HL at octave frequencies between 250-4000 Hz * Clinical diagnosis and/or treatment for schizophrenia or other psychotic disorders * Clinical diagnosis and/or treatment for neurocognitive disorders (e.g., dementia, delirium) * Presence of a severe and unmanaged, clinically diagnosed attention disorder * Head circumference greater than 60cm or weight greater than 300 pounds * History of severe claustrophobia * Currently pregnant Cohort 3 (controls matched to Cohort 2): * Presence of MRI risk factors: metal and/or electromagnetic devices (e.g., pacemakers, neurostimulators) in the body, previous shrapnel injuries, use of an intrauterine device containing metal, claustrophobia, pregnant or possibly pregnant * History of neurological / neurodegenerative disease or severe brain injury (e.g., stroke or severe traumatic brain injury) * Hearing loss, defined by pure tone thresholds \>50 dB HL at octave frequencies between 250-4000 Hz * Clinical diagnosis and/or treatment for schizophrenia or other psychotic disorders * Clinical diagnosis and/or treatment for neurocognitive disorders (e.g., dementia, delirium) * Presence of a severe and unmanaged, clinically diagnosed attention disorder * Clinically diagnosed with or treated for a speech, language, or hearing disorder * Head circumference greater than 60cm or weight greater than 300 pounds * History of severe claustrophobia * Currently pregnant
Contact & Investigator
Jason W Bohland, Ph.D.
PRINCIPAL INVESTIGATOR
University of Pittsburgh
Frequently Asked Questions
Who can join the NCT06458153 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Stroke. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06458153 currently recruiting?
Yes, NCT06458153 is actively recruiting participants. Contact the research team at j.bohland@pitt.edu for enrollment information.
Where is the NCT06458153 trial being conducted?
This trial is being conducted at Pittsburgh, United States.
Who is sponsoring the NCT06458153 clinical trial?
NCT06458153 is sponsored by University of Pittsburgh. The principal investigator is Jason W Bohland, Ph.D. at University of Pittsburgh. The trial plans to enroll 100 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.